Blood Impact Factor

Blood's IF is unusually high for a specialty journal. Most single-disease or single-organ journals sit in the 5-15 range. Blood's 19.4 reflects two things: the journal publishes across the entire breadth of hematology (basic, clinical, translational), and hematology as a field has high citation density because blood disease research feeds directly into treatment changes.

The five-year JIF (18.1) running slightly below the two-year (19.4) suggests that Blood papers get cited heavily in the first two years after publication, which is characteristic of clinical research that gets incorporated into practice quickly. This is different from basic biology journals where citation peaks later.

For career purposes, a Blood publication is universally recognized in hematology. It carries weight with grant panels, hiring committees, and promotion reviewers. The journal's ASH affiliation means it's the default prestige target for hematologists worldwide.

The decline from 25.5 (2021) to 19.4 (2024) looks concerning on paper but reflects the broader post-pandemic normalization. COVID-era hematology research (coagulation in COVID, immune responses, vaccine effects on blood) inflated citations in 2020-2021. The current 19.4 is likely Blood's structural baseline, which is still excellent for a specialty journal.

Blood's editors want papers that the hematology community will use. That sounds obvious, but it means different things for different paper types:

For basic hematology: The mechanism must connect to blood cell biology or blood disease. A paper about a transcription factor that happens to be expressed in blood cells isn't automatically Blood material. The hematology has to be the point, not the model system.

For clinical hematology: The evidence needs to change or inform clinical practice. A small case series without a clear management implication usually gets redirected. The editors want papers that practicing hematologists will cite when making treatment decisions.

For translational work: The bench-to-bedside bridge needs to be visible. Animal model data is fine, but the path to human relevance should be plausible, not speculative.

Submit if:

• the finding advances hematology in a way that the community will build on or use clinically
• the paper covers any area of blood biology or blood disease (the scope is intentionally broad)
• the evidence quality matches the claim (rigorous methodology, appropriate statistics)
• you want the ASH flagship's audience and credibility

Think twice if:

• the hematology connection is incidental (the paper is really immunology, oncology, or biochemistry)
• Blood Advances would reach the same audience with a faster, less competitive review
• Leukemia or another disease-specific journal would give better visibility for the specific topic
• the finding is incremental for hematology even if technically sound

A pre-submission review can help assess whether the hematology framing and evidence strength meet Blood's editorial expectations.

What is the Blood journal impact factor?

19.4 (2024 JCR), with a five-year JIF of 18.1. Q1 in hematology.

Is Blood a top-tier hematology journal?

Yes. It's the ASH flagship and the highest-impact dedicated hematology journal.

How does Blood compare to Nature Immunology?

Blood (19.4) has a lower IF than Nature Immunology (27.6), but Blood is the top hematology journal specifically. Nature Immunology covers all of immunology, not hematology specifically.

Is the Blood IF declining?

It has come down from the pandemic peak of 25.5 (2021) to 19.4 (2024). This is consistent with the broader normalization pattern across biomedical journals and likely represents Blood's stable structural baseline.